About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 508902, 12 pages
http://dx.doi.org/10.1155/2012/508902
Research Article

Epicatechin Used in the Treatment of Intestinal Inflammatory Disease: An Analysis by Experimental Models

1Morphology Department, Biosciences Institute, UNESP-University Estadual Paulista, P.O. Box 510, 18618-970 Botucatu, SP, Brazil
2Pharmacology Department, Biosciences Institute, UNESP-University Estadual Paulista, P.O. Box 510, 18618-970 Botucatu, SP, Brazil
3Physiology Department, Biosciences Institute, UNESP-University Estadual Paulista, P.O. Box 510, 18618-970 Botucatu, SP, Brazil

Received 15 May 2012; Accepted 11 December 2012

Academic Editor: Wagner Vilegas

Copyright © 2012 Paulo César de Paula Vasconcelos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. This study was pathway of (−)-epicatechin (EC) in the prevention and treatment of intestine inflammation in acute and chronic rat models. Methods. Intestine inflammation was induced in rats using TNBS. The morphological, inflammatory, immunohistochemical, and immunoblotting characteristics of colon samples were examined. The effects of EC were evaluated in an acute model at doses of 5, 10, 25, and 50 mg/kg by gavage for 5 days. The chronic colitis model was induced 1st day, and treated for 21 days. For the colitis relapse model, the induction was repeated on 14th. Results. EC10 and EC50 effectively reduced the lesion size, as assessed macroscopically; and confirmed by microscopy for EC10. The glutathione levels were higher in EC10 group but decreased COX-2 expression and increased cell proliferation (PC) were observed, indicating an anti-inflammatory activity and a proliferation-stimulating effect. In the chronic colitis model, EC10 showed lower macroscopic and microscopic lesion scores and increase in glutathione levels. As in the acute model, a decrease in COX-2 expression and an increase in PC in EC10, the chronic model this increase maybe by the pathway EGF expression. Conclusion. These results confirm the activity of EC as an antioxidant that reduces of the lesion and that has the potential to stimulate tissue healing, indicating useful for preventing and treating intestine inflammation.